6.5 C
New York
Thursday, October 21, 2021

In this group, Covid vaccines provide lower protection against SARS-CoV-2 infection

Must Read

Chronic Pain: New painkiller technique without side effects and drug addiction

Innovative non-pharmacological pain management practice developed by scientists - This is how the technique works

Experts identify a new drug that can help diabetic patients recover faster after heart attack

A new study by the University of Oxford's researchers has found a drug that may help repair heart function in...

Study says this drink could reduce death risk from chronic liver disease by 49%

Chronic liver disease is also known as the progressive reduction of liver function over a period of...
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

“Being vaccinated is associated with a 65% efficacy after one dose and about 78% efficacy at reducing COVID infection after the second dose,” reports new study.

For the first time, new research indicates that individuals with cirrhosis who get the mRNA COVID-19 vaccine had a better chance of avoiding more severe consequences including hospitalization and death.

Vaccines, on the other hand, provide less protection against SARS-CoV-2 infection and take longer to work in this group.

Before this study, which was published in JAMA Internal Medicine on July 13, it was unclear how much protection the vaccinations provided to individuals with cirrhosis. Most individuals with cirrhosis and other chronic illnesses were excluded from the vaccination studies.

The results of the study shows that”

Being vaccinated is associated with a 65% efficacy after one dose and about 78% efficacy at reducing COVID infection after the second dose

said Dr. John, affiliate associate professor at the University of Miami Miller School of Medicine and chief of hepatology at the Bruce W. Carter VA Medical Center in Miami.

Patients with cirrhosis who are vaccinated might still get the infection, but they are unlikely to die or get hospitalized with COVID-19

The researchers compared the data, collected between December 18, 2020, and March 17, 2021, of 20,037 individuals with cirrhosis who got at least one dose of the Pfizer or Moderna mRNA vaccination at the Veterans Health Administration throughout the country.

They compared infections and outcomes in this group to infections and outcomes in another 20,037 cirrhotic individuals with comparable COVID-19 risks who were not vaccinated.

The results of the study were “very impressive”.

After 28 days, vaccination was linked to a 100 percent decrease in COVID-19 hospitalization and mortality. In the vaccinated group, no one died from COVID-19, while there were two fatalities in the unvaccinated group.

When compared to individuals with compensated cirrhosis with excellent liver function, there was a tendency toward poorer vaccination protection in people with decompensated cirrhosis—defined as people who suffer symptoms from their liver not functioning properly.

Photo by FREDERIC J. BROWN/AFP via Getty Images

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -